On March 26, 2026, Rhythm Pharmaceuticals announced that the European Medicines Agency's committee recommended expanding the marketing authorization for IMCIVREE to treat obesity in individuals 4 years and older with hypothalamic obesity. This event is significant as it suggests potential growth in the treatment's market presence.